Modified Rankin Scale
Assessment of neurologic disability
Modified Rankin Scale
Grade 0
No symptoms at all
No symptoms at all
Grade 1
No significant disability despite symptoms: able to carry out all usual duties and activities
No significant disability despite symptoms: able to carry out all usual duties and activities
Grade 2
Slight disability: unable to carry out all previous activities but able to look after own affairs without assistance
Slight disability: unable to carry out all previous activities but able to look after own affairs without assistance
Grade 3
Moderate disability: requiring some help, but able to walk without assistance
Moderate disability: requiring some help, but able to walk without assistance
Grade 4
Moderately severe disability: unable to walk without assistance, and unable to attend to own bodily needs without assistance
Moderately severe disability: unable to walk without assistance, and unable to attend to own bodily needs without assistance
Grade 5
Severe disability: bedridden, incontinent, and requiring constant nursing care and attention
Severe disability: bedridden, incontinent, and requiring constant nursing care and attention
Grade 6
Dead
Dead
Επιπλέον πληροφορίες
Οδηγίες και παραπομπές
Προειδοποίηση
Αυτό το εργαλείο προορίζεται μόνο για εκπαιδευτικούς σκοπούς, δεν αντιπροσωπεύει και δεν αντικαθιστά επαγγελματικές συμβουλές. Αυτό το εργαλείο δεν πρέπει να χρησιμοποιείται για την παροχή ιατρικών διαγνώσεων ή/και ιατρικών θεραπειών.
General description
Stroke is one of the leading causes of death and disability worldwide. However, the total burden of poststroke disability can be challenging to quantify.
The modified Rankin Scale (mRS) is a 7-level, clinician-reported measure of global disability in patients post-stroke. It is used to categorize the level of functional independence with reference to pre-stroke activities.
The scale was originally introduced in 1957 by Dr. John Rankin as a 5-level scale ranging from 1 to 5. It was later modified and the modern (modified) version differs from Rankin's original scale mainly in the addition of grade 0, indicating a lack of symptoms, and the addition of grade 6 indicating death.
The mRS has become the most widely employed clinical outcome measure in clinical trials and in large-scale stroke care quality improvement programs. It is formally recommended by regulatory agencies and clinical trial methodology consensus groups worldwide for use in acute stroke clinical trials.
Stroke is one of the leading causes of death and disability worldwide. However, the total burden of poststroke disability can be challenging to quantify.
The modified Rankin Scale (mRS) is a 7-level, clinician-reported measure of global disability in patients post-stroke. It is used to categorize the level of functional independence with reference to pre-stroke activities.
The scale was originally introduced in 1957 by Dr. John Rankin as a 5-level scale ranging from 1 to 5. It was later modified and the modern (modified) version differs from Rankin's original scale mainly in the addition of grade 0, indicating a lack of symptoms, and the addition of grade 6 indicating death.
The mRS has become the most widely employed clinical outcome measure in clinical trials and in large-scale stroke care quality improvement programs. It is formally recommended by regulatory agencies and clinical trial methodology consensus groups worldwide for use in acute stroke clinical trials.
References
Van Swieten, J. C., et al. "Interobserver agreement for the assessment of handicap in stroke patients." stroke 19.5 (1988): 604-607.
Έκδοση
1
Σχετικά με αυτό το εργαλείο
Stroke is one of the leading causes of death and disability worldwide. However, the total burden of poststroke disability can be challenging to quantify.
The modified Rankin Scale (mRS) is a 7-level, clinician-reported measure of global disability in patients post-stroke. It is used to categorize the level of functional independence with reference to pre-stroke activities.
The scale was originally introduced in 1957 by Dr. John Rankin as a 5-level scale ranging from 1 to 5. It was later modified and the modern (modified) version differs from Rankin's original scale mainly in the addition of grade 0, indicating a lack of symptoms, and the addition of grade 6 indicating death.
The mRS has become the most widely employed clinical outcome measure in clinical trials and in large-scale stroke care quality improvement programs. It is formally recommended by regulatory agencies and clinical trial methodology consensus groups worldwide for use in acute stroke clinical trials.
The modified Rankin Scale (mRS) is a 7-level, clinician-reported measure of global disability in patients post-stroke. It is used to categorize the level of functional independence with reference to pre-stroke activities.
The scale was originally introduced in 1957 by Dr. John Rankin as a 5-level scale ranging from 1 to 5. It was later modified and the modern (modified) version differs from Rankin's original scale mainly in the addition of grade 0, indicating a lack of symptoms, and the addition of grade 6 indicating death.
The mRS has become the most widely employed clinical outcome measure in clinical trials and in large-scale stroke care quality improvement programs. It is formally recommended by regulatory agencies and clinical trial methodology consensus groups worldwide for use in acute stroke clinical trials.
